Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q3 2023 [Yahoo! Finance]
Allakos Inc. (ALLK)
Last allakos inc. earnings: 11/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.allakos.com/investor-relations
Company Research
Source: Yahoo! Finance
Net loss widened to $45.6 million in Q3 2023, up from $30.8 million in the same period last year. Allakos ended the quarter with $193.9 million in cash, cash equivalents, and investments. Key clinical milestones anticipated in late Q4 2023 to Q1 2024 for lirentelimab studies. Warning! GuruFocus has detected 2 Warning Signs with ALLK. On November 13, 2023, Allakos Inc ( NASDAQ:ALLK ) released its 8-K filing , detailing the company's financial results for the third quarter ended September 30, 2023, and providing a business update. The biotechnology firm, which focuses on developing antibodies for allergic, inflammatory, and proliferative diseases, reported significant developments in its clinical programs alongside its financial performance. Financial Performance Overview Allakos Inc ( NASDAQ:ALLK ) experienced a substantial increase in research and development expenses, which rose to $36.7 million in the third quarter of 2023, up from $18.4 million in the same quarter of t
Show less
Read more
Impact Snapshot
Event Time:
ALLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLK alerts
High impacting Allakos Inc. news events
Weekly update
A roundup of the hottest topics
ALLK
News
- Kuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmPR Newswire
- All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Allakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersGlobeNewswire
- Allakos Inc. (NASDAQ: ALLK) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $3.00 price target on the stock.MarketBeat
ALLK
Earnings
- 11/6/24 - Beat
ALLK
Sec Filings
- 12/9/24 - Form 4
- 12/9/24 - Form 4
- 12/6/24 - Form 144
- ALLK's page on the SEC website